BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026

Reuters

Jan 13

BRIEF-Edgewise <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Provides Corporate Updates And Highlights Priorities For 2026

Jan 13 (Reuters) - Edgewise Therapeutics Inc EWTX.O:

EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLIGHTS PRIORITIES FOR 2026
EDGEWISE THERAPEUTICS INC - ANTICIPATE PHASE 2 RESULTS FOR EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY $(HCM)$ IN FIRST HALF OF 2026
EDGEWISE THERAPEUTICS INC - PREPARE FOR NDA SUBMISSION FOR SEVASEMTEN IN BECKER IN H1 2027
EDGEWISE THERAPEUTICS INC - TO INITIATE EDG-7500 PHASE 3 TRIAL IN INDIVIDUALS WITH OBSTRUCTIVE AND NONOBSTRUCTIVE HCM IN SECOND HALF OF 2026

Source text: ID:nPn9hkJyTa

Further company coverage: EWTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603845066"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603845066\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603845066?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603845066","market":"fut","top_or_hot":-1,"title":"BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Corporate Updates And Highlights Priorities For 2026</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Edgewise Therapeutics Inc <span>EWTX.O</span>:</p><ul><li><p>EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLIGHTS PRIORITIES FOR 2026</p></li><li><p>EDGEWISE THERAPEUTICS INC - ANTICIPATE PHASE 2 RESULTS FOR EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY <a href=\"https://laohu8.com/S/HCM\">$(HCM)$</a> IN FIRST HALF OF 2026</p></li><li><p>EDGEWISE THERAPEUTICS INC - PREPARE FOR NDA SUBMISSION FOR SEVASEMTEN IN BECKER IN H1 2027</p></li><li><p>EDGEWISE THERAPEUTICS INC - TO INITIATE EDG-7500 PHASE 3 TRIAL IN INDIVIDUALS WITH OBSTRUCTIVE AND NONOBSTRUCTIVE HCM IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nPn9hkJyTa</span></p><p>Further company coverage: <span>EWTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Corporate Updates And Highlights Priorities For 2026</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Edgewise Therapeutics Inc <span>EWTX.O</span>:</p><ul><li><p>EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLIGHTS PRIORITIES FOR 2026</p></li><li><p>EDGEWISE THERAPEUTICS INC - ANTICIPATE PHASE 2 RESULTS FOR EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY <a href=\"https://laohu8.com/S/HCM\">$(HCM)$</a> IN FIRST HALF OF 2026</p></li><li><p>EDGEWISE THERAPEUTICS INC - PREPARE FOR NDA SUBMISSION FOR SEVASEMTEN IN BECKER IN H1 2027</p></li><li><p>EDGEWISE THERAPEUTICS INC - TO INITIATE EDG-7500 PHASE 3 TRIAL IN INDIVIDUALS WITH OBSTRUCTIVE AND NONOBSTRUCTIVE HCM IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nPn9hkJyTa</span></p><p>Further company coverage: <span>EWTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWTX","symbol_name":"Edgewise Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA3N1RJ0:1","article_id":"2603845066","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603845066","pubTimestamp":1768309767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026Jan 13 (Reuters) - Edgewise Therapeutics Inc EWTX.O:EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWTX":"Edgewise Therapeutics, Inc.","BK4539":"次新股","BK4007":"制药"},"translate_title":"简介–Edgewise Therapeutics提供公司最新动态并强调2026年的优先事项","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":0.9},"content_text":"BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026Jan 13 (Reuters) - Edgewise Therapeutics Inc EWTX.O:EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLIGHTS PRIORITIES FOR 2026EDGEWISE THERAPEUTICS INC - ANTICIPATE PHASE 2 RESULTS FOR EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY $(HCM)$ IN FIRST HALF OF 2026EDGEWISE THERAPEUTICS INC - PREPARE FOR NDA SUBMISSION FOR SEVASEMTEN IN BECKER IN H1 2027EDGEWISE THERAPEUTICS INC - TO INITIATE EDG-7500 PHASE 3 TRIAL IN INDIVIDUALS WITH OBSTRUCTIVE AND NONOBSTRUCTIVE HCM IN SECOND HALF OF 2026Source text: ID:nPn9hkJyTaFurther company coverage: EWTX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}